10-Q: Nexalin Technology Q1 2026 Financial Results

Nexalin Technology reports a net loss of $2.1 million for Q1 2026 while advancing clinical trials for its neurostimulation devices.

Summary

• Reported a net loss of $2,096,837 for the three months ended March 31, 2026, compared to $1,988,337 in the same period of 2025.
• Revenue decreased to $14,950 from $41,015 in the prior year period, primarily due to lower international equipment sales.
• Operating expenses increased slightly to $2,133,035, driven by higher professional fees and salaries.
• Maintained a working capital surplus of approximately $2,481,790 as of March 31, 2026.
• Sold 1,395,300 shares under the ATM program during the quarter, generating $756,421 in net proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the 'going concern' warning, material weaknesses in internal controls, and the need for significant capital to fund future clinical trials.

Positives

• Successfully entered into a Scope of Work with Lindus Health for the pivotal clinical trial of the HALO Clarity device.
• FDA formally accepted the Q-Submission for the Gen-2 SYNC system for Alzheimer's and dementia in October 2025.
• Maintained a working capital surplus of $2.48 million as of quarter-end.
• Gross margin improved to 88% in Q1 2026 compared to 66% in Q1 2025 due to a shift in revenue mix.

Negatives

• Revenue declined by 64% year-over-year.
• Net loss increased to $2.1 million.
• Material weaknesses in internal control over financial reporting persist regarding segregation of duties and IT access controls.
• The company is currently non-compliant with Nasdaq's minimum bid price requirement of $1.00 per share.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Insufficient cash resources to fund operations for the next twelve months.
• Dependence on successful FDA clearance for Gen-2 and Gen-3 devices to achieve commercial viability.
• Risk of delisting from the Nasdaq Capital Market if the minimum bid price is not regained by July 20, 2026.
• High reliance on future capital raises to fund ongoing clinical trials and operations.

Future Outlook

The company plans to focus on executing its pivotal clinical trial for the HALO Clarity device, continuing the FDA Q-Submission process for the Gen-2 SYNC system, and managing cash resources while seeking to regain Nasdaq listing compliance.

Management Comments

• Management acknowledges substantial doubt about the company's ability to continue as a going concern.
• Management is actively evaluating options to regain compliance with the Nasdaq minimum bid price requirement.
• Management plans to implement new financial accounting controls to remediate identified material weaknesses.

Industry Context

StockSavvy.ai notes that the neurostimulation sector is highly capital-intensive and regulatory-dependent. Nexalin's struggle with cash flow and Nasdaq compliance is common for early-stage medical device firms, but the focus on Alzheimer's and dementia via the SYNC system positions them in a high-growth, high-barrier-to-entry market segment.

Comparison to Industry Standards

• Revenue generation is significantly lower than established neurostimulation competitors like LivaNova or Nevro Corp.
• The company's reliance on ATM programs for liquidity is a standard but dilutive practice for small-cap medical device companies.
• The transition from development to clinical trials for the HALO device aligns with industry standard progression for Class II/III medical devices.

Corporate Governance

Legal Proceedings

• None.

Related Party Transactions

• Consulting agreement with U.S. Asian Consulting Group, LLC, involving monthly fees and stock grants.
• Sub-lease of office space through an entity controlled by the CEO.

Stakeholder Impact

• Shareholders face potential dilution from ongoing ATM program usage.
• Employees and board members are compensated partly in stock, aligning interests but increasing share count.
• Creditors and suppliers are subject to the company's liquidity constraints.

Next Steps

• Conduct pivotal clinical trial for HALO Clarity device.
• Continue FDA Q-Submission process for Gen-2 SYNC system.
• Regain Nasdaq minimum bid price compliance by July 20, 2026.
• Remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The stock is a high-risk speculative play. While the clinical progress is positive, the 'going concern' warning and Nasdaq delisting risk make it unsuitable for conservative investors until a clear path to profitability or a major partnership is established.

Keywords

neurostimulation, medical device, mental health, clinical trials, FDA, NXL, biotech